Online inquiry

IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14705MR)

This product GTTS-WQ14705MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SELP gene. The antibody can be applied in Sickle Cell Disease (SCD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_003005.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6403
UniProt ID P16109
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14705MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1134MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ5678MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ13552MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRX-302
GTTS-WQ7436MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ4301MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ8971MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ILV-094
GTTS-WQ14464MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ3448MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AZD8895
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW